Mersana

Mersana Therapeutics is a clinical-stage oncology firm that engages in developing novel cancer drugs.

Business Model:

Revenue: $11.9M

Employees: 51-200

Detailed Mersana Information

Geographic Data

Mersana headquarters map

Address: 840 Memorial Dr

City: Cambridge

State: MA

Zip: 02139

Country: US

Financial Info

Stage:

post ipo equity

Raised Last:

$175M

Raised Total:

$289M

Metrics

6,431,732Website Global Rank

1,020Website Monthly Traffic

Twitter Followers

Description

Mersana Therapeutics is a clinical-stage oncology firm that engages in developing novel cancer drugs.

Contact Phone:
+16174980020

Contact Email:

Mersana went public on 6/28/2017 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
6/28/2017

IPO Valuation:
$339M

Ticker Symbol:
MRSN

IPO Price:
$15/share

Amount Raised:
$75M

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
Announced Date Transaction Number of Investors Money Raised Lead Investors
2/2010 Debt Financing $2.5M
3/2018 IPO $92M
9/2013 Equity $14.5M New Enterprise Associates
6/2017 IPO $75M
2/2015 Series B $35M Fidelity Biosciences
New Enterprise Associates
Rock Springs Capital
4/2020 Post-IPO Equity $0 Bain Capital Life Sciences
Consonance Capital Partners
Avoro Capital Advisors
Bain Capital Life Sciences
Consonance Capital Partners
Avoro Capital Advisors
6/2016 Series C $33.1M Wellington Management Company
Arrowpoint Partners
Takeda Pharmaceutical Company Limited
New Enterprise Associates
Rock Springs Capital
7/2012 Series A 6 $27M New Enterprise Associates
Rho Ventures
ProQuest Investments
Pfizer Venture Investments
Harris and Harris Group
F-Prime Capital
New Enterprise Associates
6/2016 Series C 6 $33M ArrowMark Partners
Cormorant Asset Management
Rock Springs Capital
Wellington Management
New Enterprise Associates
Takeda
Wellington Management
ArrowMark Partners
Cormorant Asset Management
Rock Springs Capital
Wellington Management
New Enterprise Associates
Takeda
Wellington Management
3/2015 Series B 5 $35M F-Prime Capital
New Enterprise Associates
Rock Springs Capital
Pfizer Venture Investments
Elliott Sigal
F-Prime Capital
New Enterprise Associates
4/2012 Debt Financing $10M
11/2005 Venture Round 8 $21M F-Prime Capital
ProQuest Investments
Rho Capital Partners
PureTech Health
Lansing Brown Investments
Eight Roads Ventures
Cape Family Fund
180 Degree Capital
F-Prime Capital
ProQuest Investments
4/2014 Series A 2 $14.5M New Enterprise Associates
F-Prime Capital
2/2019 Post-IPO Equity $97.8M
5/2020 Post-IPO Equity $174.8M
4/2020 Post-IPO Equity 3 $65M Bain Capital Life Sciences
Consonance Capital Partners
Avoro Capital Advisors
Bain Capital Life Sciences
Consonance Capital Partners
Avoro Capital Advisors
Announced Date Name Price

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research